WHO Guideline Development Group advises against use of remdesivir for covid-19

▴ WHO Guideline Development Group advises against use of remdesivir for covid-19
Currently no evidence that it improves survival and other important measures

The antiviral drug remdesivir is not suggested for patients admitted to hospital with covid-19, regardless of how severely ill they are, because there is currently no evidence that it improves survival or the need for ventilation, say a WHO Guideline Development Group (GDG) panel of international experts in The BMJ recently.

The recommendation is part of a living guideline, developed by the World Health Organization with the methodological support of MAGIC Evidence Ecosystem Foundation, to provide trustworthy guidance on the management of covid-19 and help doctors make better decisions with their patients.

Living guidelines are useful in fast moving research areas like covid-19 because they allow researchers to update previously vetted and peer reviewed evidence summaries as new information becomes available.

Remdesivir has received worldwide attention as a potentially effective treatment for severe covid-19 and is increasingly used to treat patients in hospital. But its role in clinical practice has remained uncertain.

Today’s recommendation is based on a new evidence review comparing the effects of several drug treatments for covid-19. It includes data from four international randomised trials involving over 7,000 patients hospitalised for covid-19.

After thoroughly reviewing this evidence, the WHO GDG expert panel, which includes experts from around the world including four patients who have had covid-19, concluded that remdesivir has no meaningful effect on mortality or on other important outcomes for patients, such as the need for mechanical ventilation or time to clinical improvement.

The panel acknowledged that the certainty of evidence is low and said the evidence did not prove that remdesivir has no benefit; rather, there is no evidence based on currently available data that it does improve important patient outcomes.

But given the remaining possibility of important harm, as well as the relatively high cost and resource implications associated with remdesivir (it must be given intravenously), they judged this to be an appropriate recommendation.

They also support continued enrolment into trials evaluating remdesivir, especially to provide higher certainty of evidence for specific groups of patients.

In a linked feature article, US journalist Jeremy Hsu asks what now for remdesivir, given that it is unlikely to be the lifesaving drug for the masses that many have hoped for?

The full story of remdesivir will not be known until manufacturer Gilead releases the full clinical study reports, writes Hsu, but much will depend on whether future studies are designed to test remdesivir’s potential effectiveness.

In the meantime, he says alternative treatments, such as the well known, cheap, and widely available corticosteroid dexamethasone, that has been proved to reduce mortality among severely ill covid-19 patients, are now impacting discussions about remdesivir’s cost-effectiveness.

Tags : #AntiviralDrugRemdesivir #WHO #TheBMJ #MAGICEvidenceEcosystemFoundation #LatestPharmaNews20thNov #LatestResearhonCOVIDTreatment #GileadSciences

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

ISB DLabs in collaboration with CitiusTech launches ‘I-HEAL @ ISB 3.0’: Accelerating Digital Healthcare Innovation in IndiaDecember 10, 2024
Aditya Roy Kapur unveils PartySmart Gummies for hangover preventionDecember 10, 2024
Sightsavers India and Alcon India Inaugurate Block Resource Centre aimed to Empower Children with Visual Impairment in BankuraDecember 10, 2024
Does Music Really Change Your Memories? The Answer Will Surprise YouDecember 10, 2024
NRAI cautions restaurants about the dangers of aggregator payment gateways and deep discounting on diningDecember 09, 2024
Hot Cocoa: A Surprising Ally in Fighting Stress and Boosting Heart HealthDecember 09, 2024
What Your Headache Says About Your Health And Why It Can Be More Than Just a Temporary PainDecember 09, 2024
Hot Cocoa: A Surprising Ally in Fighting Stress and Boosting Heart HealthDecember 09, 2024
Is Your Favorite Snack a Secret Weapon Against Diabetes?December 07, 2024
Is the Fountain of Youth Hidden in Your Cells? Discover the Future of Ageing With Indian AIDecember 07, 2024
Does Your Heart Have a Mind of Its Own? Science Says Yes!December 07, 2024
Does Your Heart Have a Mind of Its Own? Science Says Yes!December 07, 2024
Heart Risks Are Shrinking Men’s Brains: What Science Reveals About Gender and AgingDecember 06, 2024
P&G India Celebrates 20 Years of P&G Shiksha with its largest ever Employee Volunteer Day Initiative across all offices and sitesDecember 06, 2024
Air India SATS Scales up Green Initiative with AeroWash Now Serving Two of India's Busiest AirportsDecember 06, 2024
The Silent Culprit Behind Osteoarthritis: Are Ultra-Processed Foods Eating Away our BonesDecember 06, 2024
From Daily Pills to 2 Shots Per Year: The Future of HIV ProtectionDecember 06, 2024
BREAKTHROUGH CLINICAL STUDY, FIRST OF ITS KIND, PROVES TRAYA CUSTOMIZED REGIMEN DELIVERS 3X* BETTER RESULTS THAN THE MOST PRESCRIBED HAIR GROWTH SERUM December 06, 2024
The Airborne Mutation: Is Bird Flu Becoming a Human Threat? December 05, 2024
Aster CMI Hospital collaborate with Government of Arunachal Pradesh Provide Affordable Liver Transplantation Services.December 05, 2024